The Realest Longevity Guru - EP 85 Alex Colville
Summary
Host Ashley Vance interviews Alex Colville, co-founder of longevity VC firm Age One, to cut through the hype in the aging field. Colville, a Stanford genetics PhD, discusses the scientific validity of interventions like GLP-1s, the promise of cellular reprogramming, and why he prioritizes high-impact therapies over personal biohacking. He shares insights on investment trends, the role of influencers, and the realistic timeline for extending human healthspan.
Topics discussed
Introduction to the guest and their influence in longevity
Small talk about curling and the guest's background
Guest's early career and motivation for aging research
Academic work with David Sinclair and early investments
Regeneration in nature: axolotls, livers, and human potential
Biological reset: DNA cleanup and reproduction
The current state of the aging field: hype vs. reality
Critique of popular longevity advice and basic science wins
IGF-1 signaling and the origin of the firm's name
Personal health habits: fasting, diet, and supplements
GLP-1s: mechanisms, risks, and personality changes
Future of GLP-1s and muscle-building interventions
Cellular reprogramming: Yamanaka factors and stem cells
Guest's PhD research on partial reprogramming
Extreme biology: hibernators, whales, and cancer resistance
Human genetics and RNA therapies for disease prevention
CRISPR technology: current status and future potential
Altos Labs: secrecy, reprogramming, and competitive dynamics
Calico and the search for a definitive aging win
How the team tracks research and government initiatives
AI in drug discovery and the rise of China in biotech
Speculative tech: virtual cells and organ preservation
Conclusion, sponsorships, and sign-off
Listen ad-free on Castria